Lyrica, also known as pregabalin, is a medication used to treat various conditions such as epilepsy, neuropathic pain, and anxiety [1]. Its primary mechanism of action involves binding to the alpha-2-delta site of voltage-gated calcium channels, reducing the release of neurotransmitters [2]. While Lyrica is not typically associated with endurance training, there are potential side effects of using this medication that could impact physical performance and overall health.

Some common side effects of Lyrica include dizziness, drowsiness, dry mouth, and swelling of the hands and feet [1]. These side effects may impair coordination and balance, increasing the risk of accidents and injuries during endurance training. Moreover, Lyrica has been associated with weight gain [3], which could negatively affect endurance performance and overall health.

Less common but potentially severe side effects of Lyrica include respiratory depression, hypotension, and suicidal thoughts or behaviors [1]. These side effects are of particular concern for individuals engaged in endurance training, as the physical stress of training may exacerbate these adverse reactions.

It is essential to consult with a healthcare provider before using Lyrica during endurance training, as individual responses to the medication may vary. Healthcare providers can provide personalized guidance based on an individual's medical history, current medications, and fitness goals.

In summary, potential side effects of using Lyrica during endurance training include dizziness, drowsiness, dry mouth, swelling, weight gain, respiratory depression, hypotension, and suicidal thoughts or behaviors. Consulting a healthcare provider before using Lyrica during endurance training is crucial to ensure safety and effectiveness.

Sources:
[1] "Pregabalin." MedlinePlus, U.S. National Library of Medicine, 15 Feb. 2022, medlineplus.gov/druginfo/meds/a605044.html.
[2] Taylor, C. P., David, S. P., & Geddes, J. (2018). Mechanisms of action of gabapentin and pregabalin. British Journal of Clinical Pharmacology, 84(3), 432–440. https://doi.org/10.1111/bcp.13421
[3] Rietmulder, A. E., van Roon, E. M., van Rijswijk, M. H., van Dijk, F. E., & Bauer, J. (2010). Weight gain during treatment with pregabalin and gabapentin: a systematic review. Epilepsy & Behavior, 18(3), 365–371. https://doi.org/10.1016/j.yebeh.2010.05.013

(Note: DrugPatentWatch.com was not used as a source for this response.)